For more than 80 years, men have been told that testosterone fuels prostate cancer. But a more nuanced picture has emerged ...

The results to be presented by Prof Emmett at the EAU Congress 2026 will expand on the earlier findings that the trial met its primary endpoint, demonstrating that 64 Cu-SAR-bisPSMA positron emission ...

Assessments used to calculate cardiovascular disease risk in the general population may not have the same predictive power ...

There is a shadow disease that often lurks unnoticed, growing quietly within a man’s body which is hidden behind the mundane routine of daily life, masked by ag ...

PYLCLARI® provides solutions to a wider patient group across Poland where there is high demand and unmet need PARIS, Dec. 23, ...

After a GP dismissed his symptoms, Darren Abramson was fast-tracked to a private hospital where he was given life-changing ...

Treatments for localised prostate cancer have long been aimed at treating the whole prostate, either by surgical removal or by radiotherapy. However ...

Coversure Insurance Brokers has launched a network-wide prostate cancer screening initiative, funding free prostate-specific ...

Investigators compared PSA90 response between new users of apalutamide vs abiraterone for mCSPC using a large US cohort.

MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides a precision medicine portfolio update in relation to: ...

A community health initiative offering 300 free prostate‑specific antigen (PSA) screenings to the public has been launched.

MELBOURNE, Australia and INDIANAPOLIS, /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix') today ...